Skip to content
10-Q

Quarterly Report

Maravai LifeSciences Holdings, Inc. MRVI

0001823239-26-000024

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 146.43M sh
Shares Diluted Q1 2026 · Mar 31, 2025 143.43M sh
Capex Q1 2026 · Mar 31, 2026 $4.44M
Capex restated Q1 2026 · Mar 31, 2025 $4.5M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $8.67M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.39M
Long Term Debt Q1 2026 · Mar 31, 2026 $235.57M
Long Term Debt Q1 2026 · Dec 31, 2025 $286.33M
Short Term Debt Q1 2026 · Mar 31, 2026 $5.44M
Short Term Debt Q1 2026 · Dec 31, 2025 $5.44M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $165.92M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $216.89M
Stockholders Equity Q1 2026 · Mar 31, 2026 $211.56M
Stockholders Equity Q1 2026 · Dec 31, 2025 $212.38M
Current Liabilities Q1 2026 · Mar 31, 2026 $42.62M
Current Liabilities Q1 2026 · Dec 31, 2025 $44.92M
Total Liabilities Q1 2026 · Mar 31, 2026 $344.13M
Total Liabilities Q1 2026 · Dec 31, 2025 $397.87M
Current Assets Q1 2026 · Mar 31, 2026 $251.74M
Current Assets Q1 2026 · Dec 31, 2025 $296.25M
Total Assets Q1 2026 · Mar 31, 2026 $713.22M
Total Assets Q1 2026 · Dec 31, 2025 $770.58M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.02
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.02
Eps Basic Q1 2026 · Mar 31, 2025 −$0.21
Sga Expense Q1 2026 · Mar 31, 2026 $29.09M
Sga Expense Q1 2026 · Mar 31, 2025 $39.56M
Rd Expense Q1 2026 · Mar 31, 2026 $3.89M
Rd Expense Q1 2026 · Mar 31, 2025 $4.89M
Net Income Q1 2026 · Mar 31, 2026 −$3.73M
Net Income Q1 2026 · Mar 31, 2025 −$29.95M
Operating Income Q1 2026 · Mar 31, 2026 −$2.16M
Operating Income Q1 2026 · Mar 31, 2025 −$49.16M
Gross Profit Q1 2026 · Mar 31, 2026 $33.7M
Gross Profit Q1 2026 · Mar 31, 2025 $7.73M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $32.14M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $39.13M
Revenue Q1 2026 · Mar 31, 2026 $65.84M
Revenue Q1 2026 · Mar 31, 2025 $46.85M